•
Dec 31, 2019
Verrica Q4 2019 Earnings Report
Verrica reported financial results for Q4 2019, with the FDA accepting the New Drug Application for VP-102.
Key Takeaways
Verrica Pharmaceuticals reported a net loss of $7.6 million for the fourth quarter of 2019. The FDA accepted the New Drug Application for VP-102, with a PDUFA goal date of July 13, 2020. The company also secured $55 million in non-dilutive loan facilities.
FDA accepted the New Drug Application for VP-102 for the treatment of molluscum contagiosum.
Secured $55 million in non-dilutive loan facilities, with $35 million borrowed upon closing.
Phase 3 CAMP studies showed statistically significantly higher molluscum lesion clearance with VP-102 compared to vehicle across all body regions.
Strengthened leadership team with four strategic hires.